vs
Side-by-side financial comparison of EZCORP INC (EZPW) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $382.0M, roughly 1.9× EZCORP INC). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 11.6%, a 7.5% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 19.3%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $31.7M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 15.6%).
EZCORP, Inc. is an American pawn shop operator based in Austin, Texas which provides services across the United States and Latin America. It is a publicly traded company listed on the NASDAQ stock exchange and is the second largest pawn shop operator in the U.S. after Cash America International.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
EZPW vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $382.0M | $708.5M |
| Net Profit | $44.3M | $135.1M |
| Gross Margin | 58.4% | — |
| Operating Margin | 15.9% | 21.6% |
| Net Margin | 11.6% | 19.1% |
| Revenue YoY | 19.3% | 32.0% |
| Net Profit YoY | 42.8% | 15.5% |
| EPS (diluted) | $0.55 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $382.0M | $708.5M | ||
| Q3 25 | $336.8M | $659.9M | ||
| Q2 25 | $311.0M | $603.3M | ||
| Q1 25 | $306.3M | $558.6M | ||
| Q4 24 | $320.2M | $536.6M | ||
| Q3 24 | $294.6M | $533.3M | ||
| Q2 24 | $281.4M | $528.1M | ||
| Q1 24 | $285.6M | $511.0M |
| Q4 25 | $44.3M | $135.1M | ||
| Q3 25 | $26.7M | $111.1M | ||
| Q2 25 | $26.5M | $90.3M | ||
| Q1 25 | $25.4M | $114.6M | ||
| Q4 24 | $31.0M | $117.0M | ||
| Q3 24 | $15.2M | $96.4M | ||
| Q2 24 | $17.9M | $88.4M | ||
| Q1 24 | $21.5M | $102.6M |
| Q4 25 | 58.4% | — | ||
| Q3 25 | 59.0% | — | ||
| Q2 25 | 59.1% | — | ||
| Q1 25 | 58.3% | — | ||
| Q4 24 | 57.9% | — | ||
| Q3 24 | 59.5% | — | ||
| Q2 24 | 59.2% | — | ||
| Q1 24 | 58.7% | — |
| Q4 25 | 15.9% | 21.6% | ||
| Q3 25 | 11.0% | 21.5% | ||
| Q2 25 | 11.6% | 20.9% | ||
| Q1 25 | 11.2% | 20.3% | ||
| Q4 24 | 13.1% | 23.4% | ||
| Q3 24 | 8.8% | 21.1% | ||
| Q2 24 | 7.9% | 19.9% | ||
| Q1 24 | 9.6% | 20.4% |
| Q4 25 | 11.6% | 19.1% | ||
| Q3 25 | 7.9% | 16.8% | ||
| Q2 25 | 8.5% | 15.0% | ||
| Q1 25 | 8.3% | 20.5% | ||
| Q4 24 | 9.7% | 21.8% | ||
| Q3 24 | 5.2% | 18.1% | ||
| Q2 24 | 6.4% | 16.7% | ||
| Q1 24 | 7.5% | 20.1% |
| Q4 25 | $0.55 | $4.65 | ||
| Q3 25 | $0.35 | $3.86 | ||
| Q2 25 | $0.34 | $3.10 | ||
| Q1 25 | $0.33 | $3.67 | ||
| Q4 24 | $0.40 | $3.67 | ||
| Q3 24 | $0.20 | $3.01 | ||
| Q2 24 | $0.25 | $2.75 | ||
| Q1 24 | $0.29 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $465.9M | $497.0M |
| Total DebtLower is stronger | $518.6M | — |
| Stockholders' EquityBook value | $1.1B | $459.1M |
| Total Assets | $2.0B | $2.0B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $465.9M | $497.0M | ||
| Q3 25 | $469.5M | $285.4M | ||
| Q2 25 | $472.1M | $46.3M | ||
| Q1 25 | $505.2M | $441.4M | ||
| Q4 24 | $174.5M | $669.4M | ||
| Q3 24 | $170.5M | $656.9M | ||
| Q2 24 | $218.0M | $510.9M | ||
| Q1 24 | $229.1M | $407.0M |
| Q4 25 | $518.6M | — | ||
| Q3 25 | $518.1M | — | ||
| Q2 25 | $517.6M | — | ||
| Q1 25 | $620.5M | — | ||
| Q4 24 | $327.7M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $361.3M | — | ||
| Q1 24 | $360.9M | — |
| Q4 25 | $1.1B | $459.1M | ||
| Q3 25 | $1.0B | $293.6M | ||
| Q2 25 | $990.1M | $172.4M | ||
| Q1 25 | $851.6M | $593.6M | ||
| Q4 24 | $823.9M | $825.5M | ||
| Q3 24 | $804.6M | $881.4M | ||
| Q2 24 | $801.5M | $763.6M | ||
| Q1 24 | $800.4M | $671.5M |
| Q4 25 | $2.0B | $2.0B | ||
| Q3 25 | $2.0B | $1.8B | ||
| Q2 25 | $1.9B | $1.6B | ||
| Q1 25 | $1.8B | $1.9B | ||
| Q4 24 | $1.5B | $2.1B | ||
| Q3 24 | $1.5B | $2.1B | ||
| Q2 24 | $1.5B | $1.9B | ||
| Q1 24 | $1.5B | $1.8B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.40× | — | ||
| Q3 24 | 0.41× | — | ||
| Q2 24 | 0.45× | — | ||
| Q1 24 | 0.45× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $39.1M | $192.7M |
| Free Cash FlowOCF − Capex | $31.7M | $188.1M |
| FCF MarginFCF / Revenue | 8.3% | 26.6% |
| Capex IntensityCapex / Revenue | 2.0% | 0.6% |
| Cash ConversionOCF / Net Profit | 0.88× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $121.7M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $39.1M | $192.7M | ||
| Q3 25 | $51.3M | $246.2M | ||
| Q2 25 | $34.8M | $148.5M | ||
| Q1 25 | $36.9M | $125.8M | ||
| Q4 24 | $26.0M | $190.7M | ||
| Q3 24 | $43.3M | $149.1M | ||
| Q2 24 | $33.7M | $116.4M | ||
| Q1 24 | $15.1M | $152.7M |
| Q4 25 | $31.7M | $188.1M | ||
| Q3 25 | $35.7M | $235.5M | ||
| Q2 25 | $25.7M | $142.4M | ||
| Q1 25 | $28.6M | $115.8M | ||
| Q4 24 | $20.4M | $183.0M | ||
| Q3 24 | $24.4M | $138.5M | ||
| Q2 24 | $30.5M | $103.5M | ||
| Q1 24 | $8.6M | $147.2M |
| Q4 25 | 8.3% | 26.6% | ||
| Q3 25 | 10.6% | 35.7% | ||
| Q2 25 | 8.3% | 23.6% | ||
| Q1 25 | 9.3% | 20.7% | ||
| Q4 24 | 6.4% | 34.1% | ||
| Q3 24 | 8.3% | 26.0% | ||
| Q2 24 | 10.8% | 19.6% | ||
| Q1 24 | 3.0% | 28.8% |
| Q4 25 | 2.0% | 0.6% | ||
| Q3 25 | 4.6% | 1.6% | ||
| Q2 25 | 2.9% | 1.0% | ||
| Q1 25 | 2.7% | 1.8% | ||
| Q4 24 | 1.8% | 1.4% | ||
| Q3 24 | 6.4% | 2.0% | ||
| Q2 24 | 1.1% | 2.4% | ||
| Q1 24 | 2.3% | 1.1% |
| Q4 25 | 0.88× | 1.43× | ||
| Q3 25 | 1.92× | 2.22× | ||
| Q2 25 | 1.31× | 1.65× | ||
| Q1 25 | 1.45× | 1.10× | ||
| Q4 24 | 0.84× | 1.63× | ||
| Q3 24 | 2.85× | 1.55× | ||
| Q2 24 | 1.88× | 1.32× | ||
| Q1 24 | 0.70× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EZPW
| Merchandise | $210.1M | 55% |
| Pawn Service | $131.9M | 35% |
| Jewelry Scrap | $39.9M | 10% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
